These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 18413841

  • 1. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
    Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R.
    Clin Cancer Res; 2008 Apr 15; 14(8):2484-91. PubMed ID: 18413841
    [Abstract] [Full Text] [Related]

  • 2. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
    Nerreter T, Distler E, Köchel C, Einsele H, Herr W, Seggewiss-Bernhardt R.
    Exp Hematol; 2013 Jul 15; 41(7):604-614.e4. PubMed ID: 23466625
    [Abstract] [Full Text] [Related]

  • 3. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
    Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, Szpurka H, Maciejewski JP.
    Blood; 2008 Feb 01; 111(3):1366-77. PubMed ID: 17962511
    [Abstract] [Full Text] [Related]

  • 4. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
    Blake S, Hughes TP, Mayrhofer G, Lyons AB.
    Clin Immunol; 2008 Jun 01; 127(3):330-9. PubMed ID: 18395492
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
    Hassold N, Seystahl K, Kempf K, Urlaub D, Zekl M, Einsele H, Watzl C, Wischhusen J, Seggewiss-Bernhardt R.
    Int J Cancer; 2012 Sep 15; 131(6):E916-27. PubMed ID: 22419518
    [Abstract] [Full Text] [Related]

  • 6. Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.
    Wölfl M, Schwinn S, Yoo YE, Reß ML, Braun M, Chopra M, Schreiber SC, Ayala VI, Ohlen C, Eyrich M, Beilhack A, Schlegel PG.
    Blood; 2013 Aug 15; 122(7):1203-13. PubMed ID: 23836556
    [Abstract] [Full Text] [Related]

  • 7. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
    Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, Götz M, Guillaume P, Döhner H, Bunjes D, Schmitt M.
    Exp Hematol; 2008 Oct 15; 36(10):1297-308. PubMed ID: 18619726
    [Abstract] [Full Text] [Related]

  • 8. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
    Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Götz M, Döhner H, Bunjes D, Schmitt M.
    Br J Haematol; 2009 Jan 15; 144(2):195-205. PubMed ID: 19016717
    [Abstract] [Full Text] [Related]

  • 9. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
    Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD.
    Exp Hematol; 2009 Feb 15; 37(2):256-65. PubMed ID: 19056158
    [Abstract] [Full Text] [Related]

  • 10. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
    McCaig AM, Cosimo E, Leach MT, Michie AM.
    Br J Haematol; 2011 Apr 15; 153(2):199-211. PubMed ID: 21352196
    [Abstract] [Full Text] [Related]

  • 11. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R.
    Mol Cancer Ther; 2007 Apr 15; 6(4):1400-5. PubMed ID: 17431118
    [Abstract] [Full Text] [Related]

  • 12. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Leonard JT, Kosaka Y, Malla P, LaTocha D, Lamble A, Hayes-Lattin B, Byrd K, Druker BJ, Tyner JW, Chang BH, Lind E.
    Blood; 2021 Feb 18; 137(7):939-944. PubMed ID: 32898857
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
    Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW.
    Cell Death Differ; 2010 Sep 18; 17(9):1381-91. PubMed ID: 20300113
    [Abstract] [Full Text] [Related]

  • 14. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
    Harrington P, Dillon R, Radia D, Rousselot P, McLornan DP, Ong M, Green A, Verde A, Hussain F, Raj K, Kordasti S, Harrison C, De Lavallade H.
    Haematologica; 2023 Jun 01; 108(6):1555-1566. PubMed ID: 36700403
    [Abstract] [Full Text] [Related]

  • 15. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
    Fei F, Stoddart S, Müschen M, Kim YM, Groffen J, Heisterkamp N.
    Leukemia; 2010 Apr 01; 24(4):813-20. PubMed ID: 20111071
    [Abstract] [Full Text] [Related]

  • 16. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 17. The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T-cell function.
    Wehrstedt S, Kubis J, Zimmermann A, Bruns H, Mayer D, Grieshober M, Stenger S.
    Eur J Immunol; 2018 Nov 01; 48(11):1892-1903. PubMed ID: 30242834
    [Abstract] [Full Text] [Related]

  • 18. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R.
    Cancer Res; 2008 Dec 01; 68(23):9624-33. PubMed ID: 19047139
    [Abstract] [Full Text] [Related]

  • 19. The targeting of human and mouse B lymphocytes by dasatinib.
    Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY.
    Exp Hematol; 2015 May 01; 43(5):352-363.e4. PubMed ID: 25641047
    [Abstract] [Full Text] [Related]

  • 20. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC, Wu MH, Wei TT, Chuang SH, Chen KF, Cheng AL, Chen CC.
    Neoplasia; 2012 Jun 01; 14(6):463-75. PubMed ID: 22787428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.